84 related articles for article (PubMed ID: 30361874)
1. PAM50 for prediction of response to neoadjuvant chemotherapy for ER-positive breast cancer.
Ohara AM; Naoi Y; Shimazu K; Kagara N; Shimoda M; Tanei T; Miyake T; Kim SJ; Noguchi S
Breast Cancer Res Treat; 2019 Feb; 173(3):533-543. PubMed ID: 30361874
[TBL] [Abstract][Full Text] [Related]
2. A PAM50-Based Chemoendocrine Score for Hormone Receptor-Positive Breast Cancer with an Intermediate Risk of Relapse.
Prat A; Lluch A; Turnbull AK; Dunbier AK; Calvo L; Albanell J; de la Haba-Rodríguez J; Arcusa A; Chacón JI; Sánchez-Rovira P; Plazaola A; Muñoz M; Paré L; Parker JS; Ribelles N; Jimenez B; Bin Aiderus AA; Caballero R; Adamo B; Dowsett M; Carrasco E; Martín M; Dixon JM; Perou CM; Alba E
Clin Cancer Res; 2017 Jun; 23(12):3035-3044. PubMed ID: 27903675
[No Abstract] [Full Text] [Related]
3. Gene Expression Signatures and Immunohistochemical Subtypes Add Prognostic Value to Each Other in Breast Cancer Cohorts.
Lundberg A; Lindström LS; Harrell JC; Falato C; Carlson JW; Wright PK; Foukakis T; Perou CM; Czene K; Bergh J; Tobin NP
Clin Cancer Res; 2017 Dec; 23(24):7512-7520. PubMed ID: 28972043
[No Abstract] [Full Text] [Related]
4. Avoidance and Period-Shortening of Neoadjuvant Chemotherapy Against Triple-Negative Breast Cancer in Stages I and II: Importance of Ki-67 Labeling Index and the Recognition of Apocrine-Type Lesions.
Kubouchi K; Shimada K; Yokoe T; Tsutsumi Y
Technol Cancer Res Treat; 2020; 19():1533033820943246. PubMed ID: 32677589
[TBL] [Abstract][Full Text] [Related]
5. Race and breast cancer survival by intrinsic subtype based on PAM50 gene expression.
Kroenke CH; Sweeney C; Kwan ML; Quesenberry CP; Weltzien EK; Habel LA; Castillo A; Bernard PS; Factor RE; Kushi LH; Caan BJ
Breast Cancer Res Treat; 2014 Apr; 144(3):689-99. PubMed ID: 24604094
[TBL] [Abstract][Full Text] [Related]
6. Intrinsic subtypes and genomic signatures of primary breast cancer and prognosis after systemic relapse.
Falato C; Tobin NP; Lorent J; Lindström LS; Bergh J; Foukakis T
Mol Oncol; 2016 Apr; 10(4):517-25. PubMed ID: 26651914
[TBL] [Abstract][Full Text] [Related]
7. Neoadjuvant Chemotherapy Exerts Selection Pressure Towards Luminal Phenotype Breast Cancer.
Galli G; Bregni G; Cavalieri S; Porcu L; Baili P; Hade A; Di Salvo F; Sant M; Agresti R; Gennaro M; Folli S; De Santis MC; Paolini B; Carcangiu ML; de Braud F; Di Cosimo S
Breast Care (Basel); 2017 Dec; 12(6):391-394. PubMed ID: 29456471
[TBL] [Abstract][Full Text] [Related]
8. A phase II study of palbociclib plus letrozole plus trastuzumab as neoadjuvant treatment for clinical stages II and III ER+ HER2+ breast cancer (PALTAN).
Ademuyiwa FO; Northfelt DW; O'Connor T; Levine E; Luo J; Tao Y; Hoog J; Laury ML; Summa T; Hammerschmidt T; Guo Z; Frith A; Weilbaecher K; Opyrchal M; Aft R; Clifton K; Suresh R; Bagegni N; Hagemann IS; Iglesia MD; Ma CX
NPJ Breast Cancer; 2023 Jan; 9(1):1. PubMed ID: 36609389
[TBL] [Abstract][Full Text] [Related]
9. Molecular subtyping improves breast cancer diagnosis in the Copenhagen Breast Cancer Genomics Study.
Berg T; Jensen MB; Celik A; Talman ML; Misiakou MA; Knoop AS; Nielsen FC; Ejlertsen B; Rossing M
JCI Insight; 2024 Apr; 9(7):. PubMed ID: 38587073
[TBL] [Abstract][Full Text] [Related]
10. Magnetic resonance imaging features of breast cancer according to intrinsic subtypes: correlations with neoadjuvant chemotherapy effects.
Kawashima H; Inokuchi M; Furukawa H; Ikeda H; Kitamura S
Springerplus; 2014; 3():240. PubMed ID: 24892001
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and feasibility of neoadjuvant chemotherapy with FEC 100 followed by weekly paclitaxel for operable breast cancer.
Kawajiri H; Takashima T; Onoda N; Kashiwagi S; Noda S; Ishikawa T; Wakasa K; Hirakawa K
Oncol Lett; 2012 Oct; 4(4):612-616. PubMed ID: 23205071
[TBL] [Abstract][Full Text] [Related]
12. Clinicopathological and Genomic Identification of Breast Cancers with No Impact on Mortality.
Gámez-Casado S; Rodríguez-Pérez L; Bandera-López C; Mesas-Ruiz A; Campini-Bermejo A; Bernal-Gómez M; Zalabardo-Aguilar M; Calvete-Candenas J; Martínez-Bernal G; Atienza-Cuevas L; García-Rojo M; Benítez-Rodríguez E; Pajares-Hachero B; Bermejo-Pérez MJ; Baena-Cañada JM
Cancers (Basel); 2024 Mar; 16(6):. PubMed ID: 38539421
[TBL] [Abstract][Full Text] [Related]
13. NCAPH Drives Breast Cancer Progression and Identifies a Gene Signature that Predicts Luminal A Tumor Recurrence.
Mendiburu-Eliçabe M; García-Sancha N; Corchado-Cobos R; Martínez-López A; Chang H; Mao JH; Blanco-Gómez A; García-Casas A; Castellanos-Martín A; Salvador N; Jiménez-Navas A; Pérez-Baena MJ; Sánchez-Martín MA; Abad-Hernández MDM; Del Carmen S; Claros-Ampuero J; Cruz-Hernández JJ; Rodríguez-Sánchez CA; García-Cenador MB; García-Criado FJ; Vicente RS; Castillo-Lluva S; Pérez-Losada J
Res Sq; 2023 Oct; ():. PubMed ID: 37886490
[TBL] [Abstract][Full Text] [Related]
14. Kataegis in clinical and molecular subgroups of primary breast cancer.
Veerla S; Staaf J
NPJ Breast Cancer; 2024 Apr; 10(1):32. PubMed ID: 38658600
[TBL] [Abstract][Full Text] [Related]
15. Metronomic capecitabine combined with aromatase inhibitors for new chemoendocrine treatment of advanced breast cancer: a phase II clinical trial.
Li JW; Zuo WJ; Ivanova D; Jia XQ; Lei L; Liu GY
Breast Cancer Res Treat; 2019 Jan; 173(2):407-415. PubMed ID: 30361875
[TBL] [Abstract][Full Text] [Related]
16. Neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2 blockade for HER2-positive breast cancer (TRAIN-2): a multicentre, open-label, randomised, phase 3 trial.
van Ramshorst MS; van der Voort A; van Werkhoven ED; Mandjes IA; Kemper I; Dezentjé VO; Oving IM; Honkoop AH; Tick LW; van de Wouw AJ; Mandigers CM; van Warmerdam LJ; Wesseling J; Vrancken Peeters MT; Linn SC; Sonke GS;
Lancet Oncol; 2018 Dec; 19(12):1630-1640. PubMed ID: 30413379
[TBL] [Abstract][Full Text] [Related]
17. Adjuvant Endocrine Therapy for Women With Hormone Receptor-Positive Breast Cancer: ASCO Clinical Practice Guideline Focused Update.
Burstein HJ; Lacchetti C; Anderson H; Buchholz TA; Davidson NE; Gelmon KA; Giordano SH; Hudis CA; Solky AJ; Stearns V; Winer EP; Griggs JJ
J Clin Oncol; 2019 Feb; 37(5):423-438. PubMed ID: 30452337
[TBL] [Abstract][Full Text] [Related]
18. Regional Recurrence Risk Following a Negative Sentinel Node Procedure Does Not Approximate the False-Negative Rate of the Sentinel Node Procedure in Breast Cancer Patients Not Receiving Radiotherapy or Systemic Treatment.
Roos MM; van Steenhoven JEC; Aalders KC; Schreuder K; Burgmans JPJ; Siesling S; Elias S; van Dalen T
Ann Surg Oncol; 2019 Feb; 26(2):372-378. PubMed ID: 30387028
[TBL] [Abstract][Full Text] [Related]
19. Age-related risk factors associated with primary contralateral breast cancer among younger women versus older women.
Yoon TI; Kwak BS; Yi OV; Kim S; Um E; Yun KW; Shin HN; Lee S; Sohn G; Chung IY; Kim J; Ko BS; Lee JW; Son BH; Ahn SH; Kim HJ
Breast Cancer Res Treat; 2019 Feb; 173(3):657-665. PubMed ID: 30377870
[TBL] [Abstract][Full Text] [Related]
20. Anthracycline and taxane-based chemotherapy versus docetaxel and cyclophosphamide in the adjuvant treatment of HER2-negative breast cancer patients: a systematic review and meta-analysis of randomized controlled trials.
Caparica R; Bruzzone M; Poggio F; Ceppi M; de Azambuja E; Lambertini M
Breast Cancer Res Treat; 2019 Feb; 174(1):27-37. PubMed ID: 30465156
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
